Tag: Trop-2-directed antibody
Shanghai Fudan-Zhangjiang’s FDA018-ADC Enters Phase I Clinical Trials
The National Medical Products Administration of the People's Republic of China has accepted Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s request to allow FDA018-ADC to enter in phase...
ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27%...
Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics).
This is the conclusion from an analysis of data from the pivotal...